US2021269845A1PendingUtilityA1

Bacterial systems for analyzing ubiquitylated polypeptides

Assignee: TECH INNOVATION MOMENTUM FUND ISRAEL LIMITED PARTNERSHIPPriority: Aug 8, 2016Filed: Mar 22, 2021Published: Sep 2, 2021
Est. expiryAug 8, 2036(~10 yrs left)· nominal 20-yr term from priority
Inventors:Gali Prag
G01N 2333/9108G01N 2500/02G01N 2333/9015C12Q 1/48G01N 2500/10C12Q 1/025C12N 9/104C07K 2319/95
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Bacterial systems for analyzing ubiquitination of proteins is disclosed herein. Kits for analyzing the ubiquitination and methods for carrying out the analysis are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of determining whether an enzyme is capable of ubiquitinating a test substrate, the method comprising
 (a) expressing the enzyme in a bacterial cell;   (b) expressing ubiquitin in said bacterial cell, wherein said ubiquitin is attached to a first polypeptide fragment;   (c) expressing the test substrate in said bacterial cell, wherein said substrate is attached to a second polypeptide fragment, wherein said first polypeptide fragment associates with said second polypeptide fragment to generate a reporter polypeptide on ubiquitination of the test substrate; and   (d) analyzing for the presence of said reporter polypeptide in the bacterial cell, wherein a presence of said reporter polypeptide is indicative that the enzyme is capable of ubiquitinating the test substrate.   
     
     
         2 . The method of  claim 1 , further expressing all the enzymes of the ubiquitinating enzyme cascade of the enzyme. 
     
     
         3 . The method of  claim 1 , wherein said reporter polypeptide is a detectable polypeptide or a selectable polypeptide. 
     
     
         4 . The method of  claim 1 , wherein said enzyme is selected from the group consisting of E3 ligase, ubiquitin E1-activating enzyme and ubiquitin E2 conjugating enzyme. 
     
     
         5 . The method of  claim 3 , wherein said selectable polypeptide is a split antibiotic resistance polypeptide. 
     
     
         6 . The method of  claim 1 , wherein said first polypeptide fragment is attached to said ubiquitin via a linker and/or wherein said second polypeptide fragment is attached to said substrate via a linker. 
     
     
         7 . The method of  claim 3 , wherein said detectable polypeptide is an optically detectable signal. 
     
     
         8 . The method of  claim 1 , wherein said analyzing is effected by bimolecular complementation of an antibiotic resistance protein. 
     
     
         9 . A kit comprising:
 (i) a first polynucleotide which encodes a first polypeptide fragment which is operably linked to a bacterial regulatory sequence, and a cloning site, wherein a position of said cloning site is selected such that upon insertion of a sequence which encodes a test polypeptide into said cloning site, following expression in a bacterial cell, a fusion protein is generated which comprises said test polypeptide in frame with said first polypeptide fragment; and   (ii) a second polynucleotide comprising a second nucleic acid sequence encoding a second polypeptide fragment which is attached to ubiquitin, the second nucleic acid sequence being operably linked to a bacterial regulatory sequence, wherein said first polypeptide fragment associates with said second polypeptide fragment to generate a reporter polypeptide dependent on ubiquitination of said test polypeptide.   
     
     
         10 . The kit of  claim 9 , wherein said reporter polypeptide is a selectable polypeptide. 
     
     
         11 . The kit of  claim 9 , further comprising a third polynucleotide which encodes at least one ubiquitinating enzyme. 
     
     
         12 . The kit of  claim 9 , wherein said first polynucleotide and/or said second polynucleotide comprises a sequence which encodes at least one ubiquitinating enzyme. 
     
     
         13 . The kit of  claim 9 , wherein said at least one ubiquitinating enzyme comprises:
 (a) ubiquitin E1-activating enzyme and ubiquitin E2-conjugating enzyme; or   (b) E3 ligase.

Join the waitlist — get patent alerts

Track US2021269845A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.